Archive: Company News
Company News: Ares Genetics, a Curetis Group Company, Joins NVIDIA Inception and AWS Activate Programs
— Ares Genetics selected for NVIDIA and AWS programs to accelerate commercialization of its AI-powered Universal Pathogenome Assay – ARESupa
— NVIDIA Inception program accelerates start-ups that revolutionize industries with advancements in AI
Curetis N.V. (the “Company” and, together with its subsidiaries, “Curetis”), a developer of next-level molecular diagnostic solutions, today announced that its fully-owned subsidiary Ares Genetics has joined the NVIDIA Inception program as a community member. Read more…
Company News: Curetis Group Company Ares Genetics Wins MERCUR Innovation Prize
— Prize awarded by the Vienna Economic Chamber to the most innovative companies in Vienna
— Ares Genetics´ awarded in the category Life Sciences for its AI-powered Universal Pathogenome Assay – ARESupa
Curetis N.V. (the “Company” and, together with its subsidiaries, “Curetis”), a developer of next-level molecular diagnostic solutions, today announced that its fully-owned subsidiary Ares Genetics was awarded the 2019 MERCUR Innovation Prize by the Vienna Economic Chamber in the category Life Sciences.
Company News: Curetis Expects Near-Term U.S. FDA Decision on 510(k) Clearance of Unyvero LRT for BAL Specimens
— All formal FDA requests for additional information answered
— Interactive review ongoing as review nears completion
Curetis N.V. (the “Company” and, together with its subsidiaries, “Curetis“), a developer of next-level molecular diagnostic solutions, today announced that the Company has filed its formal response to the FDA’s AI (Additional Information request letter regarding the Company’s filing for 510(k) clearance of the Unyvero LRT – Lower Respiratory Tract Application Cartridge for bronchoalveolar lavage (BAL) samples.
Company News: Curetis Publishes Third Quarter and 9-Month Business and Financial Update
– Signed IVD partnership for Ares Genetics
– Progressed implementation of the Curetis – OpGen business combination with S4 filing
– More than tripled total contract order volume received year-over-year to EUR 3.4 million in 9M-2019
– Revenue growth of approximately 16%
– Near-term FDA decision on clearance of Unyvero LRT for BAL specimen expected
Curetis N.V. (the “Company” and, together with its subsidiaries, “Curetis“), a developer of next-level molecular diagnostic solutions, today published its third quarter and 9-months business and financial update.